Skip to contentB
BioMarin Pharmaceutical Inc
B
BMRNBioMarin Pharmaceutical Inc Q1 2018 · 10-Q
Revenue$373.45M$373.45M+22.9% vs Q1 2017 Net Income-$44.15M-$44.15MN/M vs Q1 2017 EPS Diluted-$0.26-$0.26N/M vs Q1 2017 Operating Income-$44,372,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
BioMarin Pharmaceutical Inc · CIK 1048477 · Engraved from SEC EDGAR
Free Cash Flowderived-$72,673,000N/M Margins · derivedOperating margin-11.9%−5.2 pt vs Q1 2017
Net margin-11.8%−6.5 pt vs Q1 2017
ended Mar 31, 2018 · filed Apr 27, 2018 · 27 d after period end